Nisa Investment Advisors LLC Raises Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Nisa Investment Advisors LLC increased its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 21.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,684 shares of the company’s stock after buying an additional 475 shares during the period. Nisa Investment Advisors LLC’s holdings in Vaxcyte were worth $220,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Envestnet Asset Management Inc. raised its position in shares of Vaxcyte by 12.3% in the 2nd quarter. Envestnet Asset Management Inc. now owns 47,961 shares of the company’s stock worth $3,622,000 after acquiring an additional 5,268 shares in the last quarter. Squarepoint Ops LLC acquired a new position in Vaxcyte in the second quarter valued at approximately $1,764,000. AQR Capital Management LLC grew its position in shares of Vaxcyte by 3.1% during the 2nd quarter. AQR Capital Management LLC now owns 10,860 shares of the company’s stock valued at $820,000 after acquiring an additional 328 shares during the period. The Manufacturers Life Insurance Company lifted its position in shares of Vaxcyte by 10.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 131,749 shares of the company’s stock valued at $9,948,000 after buying an additional 12,667 shares in the last quarter. Finally, Algert Global LLC raised its position in shares of Vaxcyte by 161.1% during the 2nd quarter. Algert Global LLC now owns 34,752 shares of the company’s stock worth $2,624,000 after purchasing an additional 21,442 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors.

Vaxcyte Stock Down 3.8 %

NASDAQ:PCVX opened at $88.67 on Thursday. Vaxcyte, Inc. has a 52 week low of $58.10 and a 52 week high of $121.06. The stock’s fifty day moving average is $87.48 and its two-hundred day moving average is $94.24. The stock has a market capitalization of $11.05 billion, a price-to-earnings ratio of -19.28 and a beta of 0.98.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same quarter last year, the company posted ($0.91) earnings per share. On average, sell-side analysts expect that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

PCVX has been the topic of a number of research reports. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Needham & Company LLC restated a “buy” rating and issued a $140.00 target price on shares of Vaxcyte in a report on Wednesday, November 6th. Finally, The Goldman Sachs Group started coverage on Vaxcyte in a research note on Friday, December 20th. They issued a “buy” rating and a $135.00 target price for the company. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $145.71.

Insider Buying and Selling

In other Vaxcyte news, Director Teri Loxam sold 6,250 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total transaction of $531,937.50. Following the completion of the sale, the director now directly owns 7,175 shares of the company’s stock, valued at $610,664.25. This represents a 46.55 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Jim Wassil sold 8,000 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $83.66, for a total transaction of $669,280.00. Following the completion of the sale, the chief operating officer now owns 205,695 shares of the company’s stock, valued at $17,208,443.70. This trade represents a 3.74 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 85,982 shares of company stock worth $8,108,425. Corporate insiders own 3.10% of the company’s stock.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.